CR20220132A - Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación - Google Patents

Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación

Info

Publication number
CR20220132A
CR20220132A CR20220132A CR20220132A CR20220132A CR 20220132 A CR20220132 A CR 20220132A CR 20220132 A CR20220132 A CR 20220132A CR 20220132 A CR20220132 A CR 20220132A CR 20220132 A CR20220132 A CR 20220132A
Authority
CR
Costa Rica
Prior art keywords
polysaccharide
typhi
methods
salmonella
preparation
Prior art date
Application number
CR20220132A
Other languages
English (en)
Inventor
Sambhaji Shankar Pisal
Yogesh Tukaram Hundekari
Rajeev Mhalasakant Dhere
Dattatreya Sarma Annamraju
Sunil Kumar Goel
Nikhil Dattatray Avalaskar
Anil Pirajirao Taklikar
Chandrashekhar Dwarkanath Kamat
Vishal Bharat Chavan
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of CR20220132A publication Critical patent/CR20220132A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación se refiere a nuevas composiciones de vacunas inmunogénicas monovalentes y multivalentes conjugadas de polisacáridos con proteínas que comprenden un polisacárido seleccionado de cepas de <em>Salmonela</em> serotipo <em>typhi;</em> <em>S.</em> <em>paratyphi</em> <em>A; S.</em> <em>typhimurium</em> y S. <em>enteritidis</em>, así como a métodos alternativos mejorados de fermentación de polisacáridos, purificación de polisacáridos, conjugación de polisacáridos con proteínas y formulación estable. Además, la presente divulgación se refiere a métodos para inducir en sujetos una respuesta inmunitaria contra <em>Salmonela</em> typhi y enfermedades no relacionadas con typhi y/o para reducir o prevenir <em>Salmonela</em> typhi y enfermedades no relacionadas con typhi en sujetos que usen las composiciones divulgadas en el presente documento. La vacuna produce anticuerpos bactericidas y es útil para la prevención de gastroenteritis, fiebre entérica y tifoidea.
CR20220132A 2019-09-03 2020-09-02 Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación CR20220132A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921035435 2019-09-03
PCT/IN2020/050763 WO2021044436A2 (en) 2019-09-03 2020-09-02 Immunogenic compositions against enteric diseases and methods for its preparation thereof

Publications (1)

Publication Number Publication Date
CR20220132A true CR20220132A (es) 2022-05-06

Family

ID=72659843

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220132A CR20220132A (es) 2019-09-03 2020-09-02 Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación

Country Status (20)

Country Link
US (1) US20230149524A1 (es)
EP (2) EP4249061A3 (es)
JP (1) JP2022546763A (es)
KR (1) KR20220087437A (es)
CN (1) CN114728053A (es)
AR (1) AR119884A1 (es)
AU (1) AU2020343943A1 (es)
BR (1) BR112022003892A2 (es)
CA (1) CA3149972A1 (es)
CO (1) CO2022003789A2 (es)
CR (1) CR20220132A (es)
EC (1) ECSP22031077A (es)
GB (2) GB2629746A (es)
IL (1) IL291006A (es)
JO (1) JOP20200214A1 (es)
MA (1) MA56283A1 (es)
MX (1) MX2022002693A (es)
PE (1) PE20221442A1 (es)
WO (1) WO2021044436A2 (es)
ZA (1) ZA202203368B (es)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
AU1420897A (en) * 1996-12-18 1998-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugate vaccine for (salmonella paratyphi) a
ATE446107T1 (de) 1998-08-19 2009-11-15 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n- acryloyliertem polysaccharid
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US9931397B2 (en) 2005-06-27 2018-04-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
RU2518289C2 (ru) 2006-09-13 2014-06-10 Эббви Инк, Способ получения антитела или его фрагмента с подпиткой (варианты)
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
FR2938265B1 (fr) 2008-11-12 2011-07-15 Univ Claude Bernard Lyon Procede pour le pilotage d'un traitement de depolymerisation par ultrasons d'un biopolymere hydrosoluble
MX2012006961A (es) * 2009-12-17 2012-10-03 Fina Biosolutions Llc Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
US9011871B2 (en) * 2011-11-07 2015-04-21 University Of Maryland, Baltimore Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease
US9283270B2 (en) * 2012-01-20 2016-03-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
RU2634405C2 (ru) 2012-01-30 2017-10-26 Серум Инститьют Оф Индия Лтд. Иммуногенная композиция
CN102935226B (zh) * 2012-11-16 2014-01-22 罗益（无锡）生物制药有限公司 伤寒甲型副伤寒结合疫苗及其制备方法
DK3035957T3 (da) * 2013-08-24 2020-02-17 Bharat Biotech Int Ltd Bakteriel vaccine og fremgangsmåde til fremstilling deraf
CN104383532A (zh) * 2014-12-02 2015-03-04 云南沃森生物技术股份有限公司 一种用乙肝表面抗原为载体蛋白的细菌多糖蛋白结合物疫苗及其制备方法
EA039487B1 (ru) * 2015-07-04 2022-02-01 Бхарат Байотек Интернэшнл Лимитед Комбинированные полисахаридные вакцинные композиции и способ получения бактериальных капсульных полисахаридов
EP3448424A4 (en) * 2016-04-25 2019-10-02 National Institute of Immunology NOVEL CONJUGATE FOR THE VACCINATION OF TYPHUS WITH CHEMICAL CONJUGATE OF VI-POLYSACCHARIDE AND FLAGELLIN, METHOD FOR THE PRODUCTION THEREOF AND COMPOSITION WITH THE CONJUGATE
IL264605B2 (en) 2016-08-26 2023-04-01 Serum Inst Of India Private Ltd A multivalent vaccine
KR102565771B1 (ko) * 2017-05-05 2023-08-10 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 박테리아 협막 폴리사카라이드 기반 제제로부터의 불순물의 제거 방법
CN111032078A (zh) 2017-07-18 2020-04-17 血清研究所印度私人有限公司 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها

Also Published As

Publication number Publication date
PE20221442A1 (es) 2022-09-21
CO2022003789A2 (es) 2022-04-19
EP4249061A2 (en) 2023-09-27
JOP20200214A1 (ar) 2021-03-03
EP4249061A3 (en) 2023-11-15
CA3149972A1 (en) 2021-03-11
EP4025246A2 (en) 2022-07-13
GB202204276D0 (en) 2022-05-11
ZA202203368B (en) 2022-05-25
GB2603362A (en) 2022-08-03
GB2629746A (en) 2024-11-06
MX2022002693A (es) 2022-07-12
ECSP22031077A (es) 2022-05-31
BR112022003892A2 (pt) 2022-05-24
CN114728053A (zh) 2022-07-08
AR119884A1 (es) 2022-01-19
WO2021044436A2 (en) 2021-03-11
WO2021044436A3 (en) 2021-05-27
KR20220087437A (ko) 2022-06-24
AU2020343943A1 (en) 2022-03-24
IL291006A (en) 2022-05-01
JP2022546763A (ja) 2022-11-08
US20230149524A1 (en) 2023-05-18
MA56283A1 (fr) 2023-01-31

Similar Documents

Publication Publication Date Title
MX2024006606A (es) Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
CR20210333A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
PH12017501898A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
JP2004512269A5 (es)
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
RU2012138368A (ru) 15-валентная вакцинная композиция на основе конъюгата пневмококкового полисахарида с белком
WO2010141312A3 (en) Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
JP2020114838A (ja) 百日咳菌免疫原性ワクチン組成物
Lifely et al. Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteins
CR20220132A (es) Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación
RU2013145547A (ru) Адъювант на основе низкомолекулярного пептидогликана клеточной стенки бактерий
MX2023005221A (es) Composiciones inmunogenicas para uso en vacunas neumococicas.
Donachie Vaccine development against Pasteurella haemolytica infections in sheep
Amini et al. Evaluation of the immunogenicity of diphtheria toxoid conjugated to salmonella typhimurium-derived OPS in a mouse model: a potential vaccine candidate against salmonellosis
Durando et al. Immunological features and clinical benefits of conjugate vaccines against bacteria
Underdown et al. Parenteral immunization and protection from mucosal infection
Beuvery Immunisation against bacterial meningitis
Holmgren et al. Vaccines against bacterial enteric infections
MX2015017677A (es) Vacuna multivalente que contiene porinas de s. typhi y s. typhimurium contra fiebre tifoidea, paratifoidea y salmonelosis no tifoideas.
Rivera-Patron et al. Quillaja brasiliensis leaf saponins and their nanoparticles are strong inducers of early immune responses
US20210401960A1 (en) Multivalent glycoconjugates immunogenic compositions
EA202191647A1 (ru) Композиции, содержащие конъюгаты полисахарида из streptococcus pneumoniae и белка, и способы их применения
Szu et al. Escherichia coli O157
LEVINE et al. Immunology of Enteric